[HTML][HTML] Breakthroughs in hepatitis C research: from discovery to cure

MP Manns, B Maasoumy - Nature reviews Gastroenterology & …, 2022 - nature.com
In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

[HTML][HTML] Hepatocellular carcinoma: old friends and new tricks

E Kim, P Viatour - Experimental & molecular medicine, 2020 - nature.com
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and a leading
cause of cancer-related deaths worldwide. Ninety percent of HCC cases arise from cirrhosis …

[PDF][PDF] Global distribution and prevalence of hepatitis C virus genotypes

JP Messina, I Humphreys, A Flaxman, A Brown… - …, 2015 - Wiley Online Library
Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations
in genotype prevalence. This poses a challenge to the improved development of vaccines …

[HTML][HTML] EASL recommendations on treatment of hepatitis C 2015

European Association For The Study Of The Liver - Journal of hepatology, 2015 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the …

D Roth, DR Nelson, A Bruchfeld, AM Liapakis, M Silva… - The Lancet, 2015 - thelancet.com
Background Chronic hepatitis C virus (HCV) infection in patients with stage 4–5 chronic
kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C …

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

N Afdhal, S Zeuzem, P Kwo, M Chojkier… - … England Journal of …, 2014 - Mass Medical Soc
Background In phase 2 studies, treatment with the all-oral combination of the nucleotide
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …

[PDF][PDF] Health care for women subjected to intimate partner violence or sexual violence: A clinical handbook

World Health Organization - 2014 - apps.who.int
Gesundheitliche Versorgung von Frauen, die Gewalt in der Paarbeziehung oder sexuelle Gewalt
erfahren Page 1 Gesundheitliche Versorgung von Frauen, die Gewalt in der Paarbeziehung oder …

[PDF][PDF] All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

DR Nelson, JN Cooper, JP Lalezari, E Lawitz… - …, 2015 - Wiley Online Library
Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited,
with the currently approved all‐oral regimens requiring 24‐week treatment and the addition …

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

KV Kowdley, SC Gordon, KR Reddy… - … England Journal of …, 2014 - Mass Medical Soc
Background High rates of sustained virologic response were observed among patients with
hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide …

Treatment of HCV infection by targeting microRNA

HLA Janssen, HW Reesink, EJ Lawitz… - … England Journal of …, 2013 - Mass Medical Soc
Background The stability and propagation of hepatitis C virus (HCV) is dependent on a
functional interaction between the HCV genome and liver-expressed microRNA-122 (miR …